Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.

Chem Res Toxicol. 2012 Oct 15;25(10):2067-82. doi: 10.1021/tx300075j. Epub 2012 Sep 19.

PMID:
22931300
2.

Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier.

Cheng Z, Liu H, Yu N, Wang F, An G, Xu Y, Liu Q, Guan CB, Ayrton A.

Xenobiotica. 2012 Sep;42(9):880-90. doi: 10.3109/00498254.2012.675455. Epub 2012 Apr 18.

PMID:
22509823
3.

An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development.

Reese M, Sakatis M, Ambroso J, Harrell A, Yang E, Chen L, Taylor M, Baines I, Zhu L, Ayrton A, Clarke S.

Chem Biol Interact. 2011 Jun 30;192(1-2):60-4. doi: 10.1016/j.cbi.2010.10.005. Epub 2010 Oct 21.

PMID:
20970409
4.
5.

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.

Thiel-Demby VE, Humphreys JE, St John Williams LA, Ellens HM, Shah N, Ayrton AD, Polli JW.

Mol Pharm. 2009 Jan-Feb;6(1):11-8. doi: 10.1021/mp800122b.

PMID:
19248229
6.

Role of transport proteins in drug discovery and development: a pharmaceutical perspective.

Ayrton A, Morgan P.

Xenobiotica. 2008 Jul;38(7-8):676-708. doi: 10.1080/00498250801923855 . Review.

PMID:
18668427
7.

Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics.

Groenendaal D, Freijer J, Rosier A, de Mik D, Nicholls G, Hersey A, Ayrton AD, Danhof M, de Lange EC.

Eur J Pharm Sci. 2008 Jul 3;34(2-3):149-63. doi: 10.1016/j.ejps.2008.03.003. Epub 2008 Mar 30.

PMID:
18467078
8.

Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.

Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J.

Drug Metab Dispos. 2008 Feb;36(2):452-60. Epub 2007 Oct 29.

9.

P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.

Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, Bentz J.

Biochemistry. 2006 Dec 26;45(51):15505-19. Epub 2006 Nov 30.

PMID:
17176072
10.

Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan).

Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, Ayrton AD, Clarke SE.

Drug Metab Dispos. 2006 Jun;34(6):1063-9. Epub 2006 Mar 10.

11.
12.

8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.

Heightman TD, Gaster LM, Pardoe SL, Pilleux JP, Hadley MS, Middlemiss DN, Price GW, Roberts C, Scott CM, Watson JM, Gordon LJ, Holland VA, Powles J, Riley GJ, Stean TO, Trail BK, Upton N, Austin NE, Ayrton AD, Coleman T, Cutler L.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4370-4.

PMID:
16039851
13.

Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2.

Spears KJ, Ross J, Stenhouse A, Ward CJ, Goh LB, Wolf CR, Morgan P, Ayrton A, Friedberg TH.

Biochem Pharmacol. 2005 Feb 1;69(3):415-23. Epub 2004 Dec 22.

PMID:
15652233
14.

The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J.

Biophys J. 2005 Jan;88(1):715-38. Epub 2004 Oct 22.

15.

Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier.

Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J.

J Pharm Sci. 2004 Aug;93(8):2108-23.

PMID:
15236458
16.

Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells.

Swales K, Plant N, Ayrton A, Hood S, Gibson G.

Xenobiotica. 2003 Jul;33(7):703-16.

PMID:
12893520
17.

Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man.

Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, Friedberg T.

Biochem Pharmacol. 2002 Dec 1;64(11):1569-78.

PMID:
12429346
18.

Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W.

Xenobiotica. 2002 Mar;32(3):165-206. Review.

PMID:
11958559
19.

Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.

Deeni YY, Paine MJ, Ayrton AD, Clarke SE, Chenery R, Wolf CR.

Arch Biochem Biophys. 2001 Dec 1;396(1):16-24.

PMID:
11716457
20.

Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers.

El-Sankary W, Gibson GG, Ayrton A, Plant N.

Drug Metab Dispos. 2001 Nov;29(11):1499-504.

21.

Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase.

Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, Ayrton A, Jeffrey P.

Xenobiotica. 2001 Aug-Sep;31(8-9):677-86.

PMID:
11569533
22.

Role of transport proteins in drug absorption, distribution and excretion.

Ayrton A, Morgan P.

Xenobiotica. 2001 Aug-Sep;31(8-9):469-97. Review.

PMID:
11569523
23.

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R, Sorenson M, Lee JC, Ayrton A, Griswold DE, Gallagher TF.

Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6.

PMID:
9873686
24.

Application of liquid chromatography-mass spectrometry(n) analyses to the characterization of novel glyburide metabolites formed in vitro.

Tiller PR, Land AP, Jardine I, Murphy DM, Sozio R, Ayrton A, Schaefer WH.

J Chromatogr A. 1998 Jan 23;794(1-2):15-25.

PMID:
9491553
25.

Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9.

Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ.

Xenobiotica. 1995 Mar;25(3):261-70.

PMID:
7618352
26.

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.

Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ.

Br J Clin Pharmacol. 1994 Dec;38(6):557-66.

27.

Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes.

Clarke SE, Baldwin SJ, Bloomer JC, Ayrton AD, Sozio RS, Chenery RJ.

Chem Res Toxicol. 1994 Nov-Dec;7(6):836-42.

PMID:
7696540
28.

Characterization of the inhibition of P4501A2 by furafylline.

Clarke SE, Ayrton AD, Chenery RJ.

Xenobiotica. 1994 Jun;24(6):517-26.

PMID:
7975717
29.

Extrapolation of in vitro antimutagenicity to the in vivo situation: the case for anthraflavic acid.

Ioannides C, Ayrton AD, Lewis DF, Walker R.

Basic Life Sci. 1993;61:103-10. Review. No abstract available.

PMID:
8304922
30.

Antimutagenicity of ellagic acid towards the food mutagen IQ: investigation into possible mechanisms of action.

Ayrton AD, Lewis DF, Walker R, Ioannides C.

Food Chem Toxicol. 1992 Apr;30(4):289-95.

PMID:
1628864
31.

A cytosolic oxygenase activity involved in the bioactivation of 2-aminofluorene.

Leist M, Ayrton AD, Ioannides C.

Toxicology. 1992;71(1-2):7-20.

PMID:
1729770
32.
34.

Mechanism of the in vitro antimutagenic action of retinol.

Ioannides C, Ayrton AD, Keele A, Lewis DF, Flatt PR, Walker R.

Mutagenesis. 1990 May;5(3):257-62.

PMID:
2385179
35.

The induction of P450 I proteins by aromatic amines may be related to their carcinogenic potential.

Ayrton AD, McFarlane M, Walker R, Neville S, Ioannides C.

Carcinogenesis. 1990 May;11(5):803-9.

PMID:
2335009
36.

Feprazone: an inducer of the P450 II B family of proteins in the rat.

Smith JN, Ayrton AD, Chown J, Lewis DF, Ioannides C.

J Biochem Toxicol. 1990 Spring;5(1):9-12.

PMID:
2402005
37.

Induction of the P-450 I family of proteins by polycyclic aromatic hydrocarbons: possible relationship to their carcinogenicity.

Ayrton AD, McFarlane M, Walker R, Neville S, Coombs MM, Ioannides C.

Toxicology. 1990 Jan-Feb;60(1-2):173-86.

PMID:
2315940
38.

Induction of the rat hepatic microsomal mixed-function oxidases by cimetidine.

Ioannides C, Rodrigues AD, Ayrton AD, Barnett CR, Chown J, Parke DV.

Toxicol Lett. 1989 Oct;49(1):61-8.

PMID:
2815115
39.

Preferential induction of the rat hepatic P450 I proteins by the food carcinogen 2-amino-3-methyl-imidazo[4,5-f]quinoline.

Rodrigues AD, Ayrton AD, Williams EJ, Lewis DF, Walker R, Ioannides C.

Eur J Biochem. 1989 May 15;181(3):627-31.

40.

The food pyrolysis product IQ enhances its own activation.

Ayrton AD, Williams EJ, Rodrigues AD, Ioannides C, Walker R.

Mutagenesis. 1989 May;4(3):205-7.

PMID:
2659938
41.

Metabolic activation of chemical carcinogens by hepatic preparations from streptozotocin-treated rats.

Flatt PR, Bass SL, Ayrton AD, Trinick J, Ioannides C.

Diabetologia. 1989 Feb;32(2):135-9.

PMID:
2524416
42.

Induction of the rat hepatic microsomal mixed-function oxidases by two aza-arenes. A comparison with their non-heterocyclic analogues.

Ayrton AD, Trinick J, Wood BP, Smith JN, Ioannides C.

Biochem Pharmacol. 1988 Dec 1;37(23):4565-71.

PMID:
3060123
43.

Induction of rat hepatic cytochrome P-450 I proteins by the antimutagen anthraflavic acid.

Ayrton AD, Ioannides C, Walker R.

Food Chem Toxicol. 1988 Nov-Dec;26(11-12):909-15.

PMID:
3209131
44.

The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo.

Chenery RJ, Ayrton A, Oldham HG, Norman SJ, Standring P.

Biochem Pharmacol. 1988 Apr 1;37(7):1407-14.

PMID:
3258518
45.

Anthraflavic acid inhibits the mutagenicity of the food mutagen IQ: mechanism of action.

Ayrton AD, Ioannides C, Walker R.

Mutat Res. 1988 Mar-Apr;207(3-4):121-5.

PMID:
3282161
46.

Streptozotocin-induced diabetes modulates the metabolic activation of chemical carcinogens.

Ioannides C, Bass SL, Ayrton AD, Trinick J, Walker R, Flatt PR.

Chem Biol Interact. 1988;68(3-4):189-202.

PMID:
2975197
47.

Anthraflavic acid is a potent and specific inhibitor of cytochrome P-448 activity.

Ayrton AD, Lewis DF, Ioannides C, Walker R.

Biochim Biophys Acta. 1987 Dec 18;916(3):328-31.

PMID:
3689794
48.
49.

Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig, and man.

Chenery RJ, Ayrton A, Oldham HG, Standring P, Norman SJ, Seddon T, Kirby R.

Drug Metab Dispos. 1987 May-Jun;15(3):312-7.

PMID:
2886305
50.

Coagulopathy related to dilution and hypotension during massive transfusion.

Hewson JR, Neame PB, Kumar N, Ayrton A, Gregor P, Davis C, Shragge BW.

Crit Care Med. 1985 May;13(5):387-91.

PMID:
3987316

Supplemental Content

Loading ...
Support Center